Imagio Breast Imaging System

The Imagio Breast Imaging System aims to enhance diagnostic accuracy for suspicious breast lesions by integrating optoacoustic technology with conventional ultrasound, thereby enabling the visualization of lesion vascularity and oxygen saturation based on hemoglobin's absorption of near-infrared light. This hybrid approach functions as an adjunct to standard ultrasound, providing crucial functional information that improves specificity and reduces false-positive biopsies by identifying unique physiological patterns indicative of malignancy.

The Imagio Breast Imaging System is an innovative hybrid medical device designed to improve the characterization of suspicious breast lesions (BI-RADS 3–5) initially identified via standard B-mode ultrasound. Its core methodology involves the sequential application of ultrasound for lesion localization, followed by optoacoustic (also known as photoacoustic) imaging. This second step utilizes near-infrared laser pulses; the emitted light is absorbed by hemoglobin within the lesion, generating ultrasound signals that are then detected by the system. This process allows for the creation of detailed maps depicting the lesion's vascularity and oxygen saturation levels, providing functional insights into its metabolic state and biological activity. Clinical investigations have demonstrated the Imagio system's efficacy in enhancing diagnostic specificity when used as an adjunct to conventional ultrasound. By revealing distinct vascular patterns and oxygenation states that are typically associated with cancerous tissues, the system helps differentiate malignant lesions from benign ones more accurately. This improved characterization leads to a significant reduction in the number of false-positive biopsies, thereby sparing patients from unnecessary invasive procedures and associated anxiety, while also potentially lowering healthcare costs. The system provides clinicians with additional, crucial functional information beyond the anatomical data offered by ultrasound alone, aiding in more confident decision-making regarding patient management.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the Imagio system quantitatively differentiate between benign and malignant vascular patterns beyond just increased vascularity, and what are the specific cut-off values used?; What is the reported learning curve for clinicians to achieve proficiency in interpreting the optoacoustic data from the Imagio system and integrating it into their diagnostic workflow?; Are there specific BI-RADS categories (e.g., 3 vs. 4a vs. 4b vs. 5) where the Imagio system demonstrates the most significant impact on improving diagnostic specificity or reducing unnecessary biopsies?; How does the performance of the Imagio system compare directly with other advanced breast imaging modalities, such as contrast-enhanced mammography or breast MRI, in terms of specificity, sensitivity, and cost-effectiveness for BI-RADS 3-5 lesions?; What are the long-term follow-up data on patients whose suspicious lesions were downgraded or deemed benign based on Imagio system findings, particularly regarding interval cancer rates?